These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 721947)

  • 1. Comparison of immunogenicity of a whole virion and a subunit influenza vaccine in adults.
    Ortbals DW; Liebhaber H
    J Clin Microbiol; 1978 Oct; 8(4):431-4. PubMed ID: 721947
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A one-year study of trivalent influenza vaccines in primed and unprimed volunteers: immunogenicity, clinical reactions and protection.
    Masurel N; Laufer J
    J Hyg (Lond); 1984 Jun; 92(3):263-76. PubMed ID: 6736638
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reactogenicity and immunogenicity of parenteral monovalent influenza A/Victoria/3/75 (H3N2) virus vaccine in healthy adults.
    Caplan ES; Hughes TP; O'Donnel S; Levine MM; Hornick RB
    J Infect Dis; 1977 Dec; 136 Suppl():S484-90. PubMed ID: 342622
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A TritonX-100-split virion influenza vaccine is safe and fulfills the committee for proprietary medicinal products (CPMP) recommendations for the European Community for Immunogenicity, in Children, Adults and the Elderly.
    Lina B; Fletcher MA; Valette M; Saliou P; Aymard M
    Biologicals; 2000 Jun; 28(2):95-103. PubMed ID: 10885616
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Comparison between killed subunit influenza vaccines and whole virion preparations: study of reactions and protective efficacy in children and adults].
    Profeta ML; Bigatello A; Vacchini V; Bramati L; Ferrante P
    Boll Ist Sieroter Milan; 1980 Jan; 58(6):457-74. PubMed ID: 6778485
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity and safety of a split-virion quadrivalent influenza vaccine in adults 18-60 years of age in the Republic of Korea.
    Choi WS; Noh JY; Lee J; Choi JY; Lee JS; Kim MS; Kim HS; Bang J; Lavis N; Kim WJ
    Hum Vaccin Immunother; 2018 Mar; 14(3):587-592. PubMed ID: 28933625
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reactogenicity and immunogenicity of inactivated influenza A (H1N1) virus vaccine in unprimed children. Report to the Medical Research Council Committee on influenza and other respiratory virus vaccines.
    Potter CW; Clark A; Jennings R; Schild GC; Wood JM; McWilliams PK
    J Biol Stand; 1980; 8(1):35-48. PubMed ID: 6995458
    [No Abstract]   [Full Text] [Related]  

  • 8. Serologic responses after two sequential doses of influenza A/New Jersey/76 virus vaccine in normal young adults.
    Wise TG; Dolin R; Mazur MH; Ennis FA
    J Infect Dis; 1977 Dec; 136 Suppl():S496-9. PubMed ID: 606771
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pandemic influenza A H1N1 vaccine in recipients of solid organ transplants: immunogenicity and tolerability outcomes after vero cell derived, non-adjuvanted, whole-virion vaccination.
    Lagler H; Wenisch JM; Tobudic S; Gualdoni GA; Rödler S; Rasoul-Rockenschaub S; Jaksch P; Redlberger-Fritz M; Popow-Kraupp T; Burgmann H
    Vaccine; 2011 Sep; 29(40):6888-93. PubMed ID: 21803100
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sequential immunization of laboratory personnel with influenza A/New Jersey/76 split- and whole-virus vaccines.
    Edelman R; Scheidt KB
    J Infect Dis; 1977 Dec; 136 Suppl():S500-6. PubMed ID: 606772
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Study of the immunogenicity of trivalent inactivated whole-virion influenza vaccine in human volunteers.
    Moffat MA; Pennington TH; Robertson AM; van Voorthuizen WF
    J Biol Stand; 1982 Apr; 10(2):83-90. PubMed ID: 7096364
    [No Abstract]   [Full Text] [Related]  

  • 12. [Comparative study of the effectiveness of inactivated influenza vaccine preparations].
    Ismagulov AT; Nurgaliev KN
    Zh Mikrobiol Epidemiol Immunobiol; 1983 May; (5):84-7. PubMed ID: 6880484
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the reactogenicity and immunogenicity of a split and a subunit-adjuvanted influenza vaccine in elderly subjects.
    Squarcione S; Sgricia S; Biasio LR; Perinetti E
    Vaccine; 2003 Mar; 21(11-12):1268-74. PubMed ID: 12559808
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and immunogenicity of adjuvanted inactivated split-virion and whole-virion influenza A (H5N1) vaccines in children: a phase I-II randomized trial.
    Wu J; Liu SZ; Dong SS; Dong XP; Zhang WL; Lu M; Li CG; Zhou JC; Fang HH; Liu Y; Liu LY; Qiu YZ; Gao Q; Zhang XM; Chen JT; Zhong X; Yin WD; Feng ZJ
    Vaccine; 2010 Aug; 28(38):6221-7. PubMed ID: 20638454
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Phase III randomised trial of the immunogenicity and safety of quadrivalent versus trivalent inactivated subunit influenza vaccine in adult and elderly subjects, assessing both anti-haemagglutinin and virus neutralisation antibody responses.
    van de Witte S; Nauta J; Montomoli E; Weckx J
    Vaccine; 2018 Sep; 36(40):6030-6038. PubMed ID: 29709447
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and immunogenicity of MF59-adjuvanted influenza vaccine in the elderly.
    De Donato S; Granoff D; Minutello M; Lecchi G; Faccini M; Agnello M; Senatore F; Verweij P; Fritzell B; Podda A
    Vaccine; 1999 Aug; 17(23-24):3094-101. PubMed ID: 10462245
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acceptibility and antigenicity of influenza A/Victoria/75 virus vaccines in adults of different ages.
    Gwaltney JM; Adams KF; Hendley JO
    J Infect Dis; 1977 Dec; 136 Suppl():S491-5. PubMed ID: 606770
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical trials of monovalent influenza A/New Jersey/76 virus vaccines in adults: reactogenicity, antibody response, and antibody persistence.
    Cate TR; Couch RB; Kasel JA; Six HR
    J Infect Dis; 1977 Dec; 136 Suppl():S450-5. PubMed ID: 342620
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical reactions and serologic responses in healthy children aged six to 35 months after two-dose regimens of inactivated A/New Jersey/76 influenza virus vaccines.
    Boyer KM; Cherry JD; Wright PF; Lerman SJ; Gross PA; Foy HM; Taylor JW; Noble GR
    J Infect Dis; 1977 Dec; 136 Suppl():S579-83. PubMed ID: 342630
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and immunogenicity of high-dose quadrivalent influenza vaccine in adults ≥65 years of age: A phase 3 randomized clinical trial.
    Chang LJ; Meng Y; Janosczyk H; Landolfi V; Talbot HK;
    Vaccine; 2019 Sep; 37(39):5825-5834. PubMed ID: 31431411
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.